Previous 10 |
ADC Therapeutics SA (ADCT) Q2 2020 Earnings Conference Call August 18, 2020, 08:30 ET Company Participants Amanda Hamilton - IR Officer Christopher Martin - CEO & Director Jay Feingold - Chief Medical Officer, Head, Oncology Clinical Development & Senior VP Jennifer Cre...
ADC Therapeutics (NYSE: ADCT ) : Q2 Non-GAAP EPS of -$0.51; GAAP EPS of -$2.01. More news on: ADC Therapeutics SA, Earnings news and commentary, Healthcare stocks news, , Read more ...
- On track to file BLA for Lonca for relapsed or refractory DLBCL later this year with commercial launch preparations ongoing - Completed upsized $268 million initial public offering and received first tranche of $115 million Convertible Credit Facility from Deerfield - Company to...
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it ...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...